Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study.
暂无分享,去创建一个
Philippe Lambin | Geert Bosmans | Dirk De Ruysscher | Hugo J W L Aerts | P. Lambin | H. Aerts | A. Dekker | D. de Ruysscher | G. Bosmans | A. V. van Baardwijk | M. Oellers | Andre L A J Dekker | Angela A W van Baardwijk | Michel C Oellers
[1] S. Larson,et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Lambin,et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients , 2007 .
[3] M Alber,et al. On biologically conformal boost dose optimization. , 2003, Physics in medicine and biology.
[4] Sigrid Stroobants,et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .
[5] S. Kudoh,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C C Ling,et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.
[7] Philippe Lambin,et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. , 2007, International journal of radiation oncology, biology, physics.
[8] J. Daurès,et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Nagara Tamaki,et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] J. Bradley. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. , 2005, Seminars in oncology.
[11] A H Baydush,et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. , 2004, Medical physics.
[12] Cedric Yu,et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.
[13] J P Logue,et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] Philippe Lambin,et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. , 2006, International journal of radiation oncology, biology, physics.
[15] Søren M Bentzen,et al. Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.
[16] D. Abbott,et al. Functional imaging of intratumoral hypoxia. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[17] Jean-François Daisne,et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.
[18] H. Dittmann,et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European journal of nuclear medicine and molecular imaging.
[19] Leen Paelinck,et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] Morand Piert,et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] J. García-Segura,et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. , 1999, Magnetic resonance imaging.
[22] P. Lambin,et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[23] S Mutic,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[24] H. Dittmann,et al. Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[25] Søren M Bentzen,et al. Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] Joos V Lebesque,et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.
[27] Philippe Lambin,et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. , 2007, European journal of cancer.
[28] A. Boyer,et al. Inverse planning for functional image-guided intensity-modulated radiation therapy. , 2002, Physics in medicine and biology.
[29] L. Dubois,et al. Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry , 2004, British Journal of Cancer.
[30] S. Apisarnthanarax,et al. Current Imaging Paradigms in Radiation Oncology , 2005, Radiation research.
[31] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[32] P. Dupont,et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Anne Bol,et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[34] Ladislav Pecen,et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. , 2004, Lung cancer.
[35] Suresh Senan,et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.